公开(公告)号：US20240132513A1

公开(公告)日：2024-04-25

申请号：US18235753

申请日：2023-08-18

申请人： AGENEBIO, INC.

发明人： Belew Mekonnen ,  John A. Butera ,  Jianxing Huang ,  Hemantbhai Patel

IPC分类号： C07D487/14 ,  A61K45/06 ,  A61P25/28 ,  C07D413/14 ,  C07D487/04 ,  C07D498/14 ,  C07D519/00

CPC分类号： C07D487/14 ,  A61K45/06 ,  A61P25/28 ,  C07D413/14 ,  C07D487/04 ,  C07D498/14 ,  C07D519/00

摘要： Benzazepine derivatives, compositions comprising therapeutically effective amounts of those benzazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders or associated with risk factors for cognitive impairment. In particular, it relates to the use of a α5-containing GABAA R agonist (e.g., a α5-containing GABAA R positive allosteric modulator) in treating cognitive impairment associated with central nervous system (CNS) disorders or having a risk factor associated with cognitive impairment in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease (AD), prodromal AD, post-traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of a α5-containing GABAA R agonist (e.g., a α5-containing GABAA R positive allosteric modulator) as described herein in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

公开(公告)号：US20230279021A1

公开(公告)日：2023-09-07

申请号：US18015445

申请日：2021-07-09

申请人： AGENEBIO, INC.

发明人： Deepa Gandla ,  Brian Gregg ,  Vishnumurthy Hegde ,  Stephan D. Parent ,  Travis Lee Houston

IPC分类号： C07D487/14 ,  A61K31/13 ,  A61K45/06 ,  A61K31/5517

CPC分类号： C07D487/14 ,  A61K31/13 ,  A61K45/06 ,  A61K31/5517 ,  C07B2200/13

摘要： Crystalline forms of a GABAA α5 agonist, pharmaceutical compositions and combinations comprising those crystalline forms, their use in methods of treating cognitive impairment associated with central nervous system (CNS) disorders, cognitive impairment associated with brain cancer, the brain cancer itself or Parkinson's disease psychosis and methods of producing the crystalline forms.

公开(公告)号：US20230098667A1

公开(公告)日：2023-03-30

申请号：US17786175

申请日：2020-12-18

申请人： AGENEBIO, INC.

发明人： Belew Mekonnen ,  John A. Butera ,  Jianxing Huang ,  Hemantbhai Patel ,  Qin Jiang ,  Robert Jason Herr ,  Emily Elizabeth Freeman ,  Nicholas James Mayhew

IPC分类号： A61K31/5517 ,  C07D487/14 ,  A61K31/496 ,  A61K31/5513 ,  A61K31/13 ,  A61K31/445 ,  A61K31/55 ,  A61K31/27 ,  A61P25/28

摘要： This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with CNS disorders. It also relates to the use of an α5-containing GABAA receptor agonist (e.g, an α5-containing GABAA receptor positive allosteric modulator) in treating cognitive impairment associated with CNS disorders in a subject in need or at risk thereof, including age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI, Age-Associated Memory Impairment, Age Related Cognitive Decline, dementia, Alzheimer's Disease (AD), prodromal AD, PTSD, schizophrenia, bipolar disorder, ALS, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease, autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of an α5-containing GABAA receptor agonist (e.g., an α5-containing GABAA receptor positive allosteric modulator) in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

公开(公告)号：US20220274996A1

公开(公告)日：2022-09-01

申请号：US17592679

申请日：2022-02-04

申请人： AGENEBIO, INC.

发明人： Belew Mekonnen ,  John A. Butera ,  Jianxing Huang

IPC分类号： C07D487/14 ,  A61K45/06 ,  A61K31/13 ,  A61K31/551 ,  A61K31/496 ,  A61K31/445 ,  A61K31/55 ,  A61K31/27 ,  A61P25/00 ,  A61K31/5517

摘要： This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction.

公开(公告)号：US10925834B2

公开(公告)日：2021-02-23

申请号：US15574824

申请日：2016-05-20

申请人： AgeneBio, Inc.

发明人： Michela Gallagher ,  Sharon Rosenzweig-Lipson ,  Elsie Melsopp ,  Jack Lawrence James

IPC分类号： A61K9/20 ,  A61K9/00 ,  A61K31/4015

摘要： This invention relates to novel extended release pharmaceutical compositions of levetiracetam and preparations and characterizations thereof. This invention further relates to using these extended release pharmaceutical compositions of levetiracetam for the treatment of cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof.

公开(公告)号：US20130237545A1

公开(公告)日：2013-09-12

申请号：US13885569

申请日：2011-11-15

申请人： John A. Lowe, III

发明人： John A. Lowe, III

IPC分类号： C07D237/24 ,  C07D413/14 ,  C07D413/04 ,  C07D401/04 ,  C07D403/04

CPC分类号： A61K31/501 ,  A61K31/50 ,  C07D237/24 ,  C07D401/04 ,  C07D403/04 ,  C07D413/04 ,  C07D413/14

摘要： This invention relates to pyridazine derivatives, compositions comprising therapeutically effective amounts of those pyridazine derivatives and methods of using those derivatives or compositions in treating central nervous system (CNS) disorders with cognitive impairment that are responsive to agonists of α5 subunit containing GABAA receptor, e.g., age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia and cancer-therapy-related cognitive impairment.

摘要翻译： 本发明涉及哒嗪衍生物，包含治疗有效量的那些哒嗪衍生物的组合物和使用这些衍生物或组合物治疗对具有含有GABA A受体的α5亚基的激动剂有反应的认知障碍的中枢神经系统（CNS）障碍的方法， 年龄相关的认知障碍，轻度认知障碍（MCI），痴呆，阿尔茨海默病（AD），前驱性AD，创伤后应激障碍（PTSD），精神分裂症和癌症治疗相关的认知障碍。

公开(公告)号：US20130237530A1

公开(公告)日：2013-09-12

申请号：US13885561

申请日：2011-11-15

申请人： John A. Lowe, III

发明人： John A. Lowe, III

IPC分类号： C07D487/14

CPC分类号： C07D487/14

摘要： This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating central nervous system (CNS) disorders with cognitive impairment that are responsive to agonists of α5 subunit containing GABAA receptor, e.g., age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia and cancer-therapy-related cognitive impairment.

摘要翻译： 本发明涉及苯并二氮杂衍生物，包含治疗有效量的那些苯并二氮杂衍生物的组合物和使用这些衍生物或组合物治疗具有认知障碍的中枢神经系统（CNS）障碍的方法，所述认知障碍对含有GABA A受体的α5亚基的激动剂是有反应的， 年龄相关的认知障碍，轻度认知障碍（MCI），痴呆，阿尔茨海默病（AD），前驱性AD，创伤后应激障碍（PTSD），精神分裂症和癌症治疗相关的认知障碍。